NEPHROS INC
Nephros develops and sells point-of-use water filtration products for medical and commercial applications. Its medical portfolio includes infection-control microfilters and ultrafilters, as well as ultrafilters for dialysis water and bicarbonate concentrate. Its commercial filters address taste, odor, scale, particulates, lead, cysts and Total PFAS. The products serve hospitals, dialysis facilities, foodservice and hospitality businesses, and customers in industries including manufacturing, laboratories, aviation and government. Nephros sells medical filters mainly through distributors, supplemented by a direct salesforce focused on hospitals and dialysis customers. Commercial products are sold through direct and distributor channels. Nephros does not manufacture its medical filtration products, while it makes some commercial filters at its South Orange, New Jersey facility. The company is headquartered in South Orange, New Jersey.
No SEC Form 4 filings for $NEPH in the last 30 days.
See all $NEPH insider activity →Nephros reported Q3 GAAP EPS of $0.05, beating estimates by $0.03, with revenue of $5.6M, up 16.7% Y/Y and exceeding expectations by $0.11M. Net income rose to $0.5M from $0.3M Y/Y, and adjusted EBITDA increased to $0.6M from $0.4M.
Nephros, Inc. (NEPH) reported Q3 2026 net revenue growth of 18% to $5.6M, net income of $0.5M, and adjusted EBITDA of $0.6M. The company added 31 new customer sites, expanding its active base to 1,766. CEO Robert Banks highlighted growth in healthcare and the Nephros Water Institute's educational initiatives. The company will host a conference call to discuss results.
Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NEPH (NEPHROS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent NEPH coverage spans financial news, earnings and market movers.
Earnings beat may prompt short-term price appreciation.
Quarterly earnings beat expectations with revenue and profit growth.
Modest pre‑market gain reflects mild optimism.
The filing provides a fresh earnings datapoint with a material one-time tariff refund that also affects gross margin and receivables.
Nephros is scheduled to release its Q1 2026 financial results on May 7, 2026, after market close, with a conference call at 4:30 PM ET. This event could lead to increased volatility in the company's stock around the release date.
AlphAI scores every news story that mentions NEPH with an AI model for sentiment and relevance, and aggregates insider trades from NEPHROS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nephros reported Q3 GAAP EPS of $0.05, beating estimates by $0.03, with revenue of $5.6M, up 16.7% Y/Y and exceeding expectations by $0.11M. Net income rose to $0.5M from $0.3M Y/Y, and adjusted EBITDA increased to $0.6M from $0.4M.
Nephros, Inc. (NEPH) reported Q3 2026 net revenue growth of 18% to $5.6M, net income of $0.5M, and adjusted EBITDA of $0.6M. The company added 31 new customer sites, expanding its active base to 1,766. CEO Robert Banks highlighted growth in healthcare and the Nephros Water Institute's educational initiatives. The company will host a conference call to discuss results.
Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
NEPHROS INC (NEPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026 Record Second-Quarter Net Revenue Growth of 36% to $6 million; Core Programmatic Revenue Grew by 27% Yea
Nephros, Inc. announced it will file its first-quarter 2026 financial results on Thursday, May 7, 2026, after market close and will host a conference call the same day at 4:30 PM ET. The company, a water technology provider, detailed the dial-in information for the conference call and replay access. An audio archive will be available on the Nephros Investor Relations page.
Nephros, Inc. has expanded its water safety support capabilities with the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire. This allows Nephros to offer consultative support and Water Management Program development services to healthcare facilities and other complex buildings. The company believes this new offering will provide additional value to customers, strengthen its overall value proposition, and open a new revenue stream through chargeable consulting services.
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability
SOUTH ORANGE, N.J., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nephros, Inc. ( NASDAQ:NEPH ) , a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 ...
SOUTH ORANGE, N.J., July 31, 2025 ( GLOBE NEWSWIRE ) -- Nephros, Inc. NEPH, a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 07, 2025 after market ...
